NRx Pharmaceuticals, Inc. (NASDAQ:NRXP – Free Report) – Stock analysts at HC Wainwright decreased their Q2 2027 EPS estimates for shares of NRx Pharmaceuticals in a research report issued to clients and investors on Tuesday, November 3rd. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($0.17) for the quarter, down from their previous forecast of ($0.15). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for NRx Pharmaceuticals’ current full-year earnings is ($1.14) per share. HC Wainwright also issued estimates for NRx Pharmaceuticals’ Q3 2027 earnings at ($0.11) EPS, Q4 2027 earnings at ($0.04) EPS, FY2027 earnings at ($0.62) EPS and FY2028 earnings at $0.03 EPS.
Several other research firms also recently weighed in on NRXP. Zacks Research downgraded shares of NRx Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Wednesday, August 26th. UBS Group reaffirmed a “buy” rating on shares of NRx Pharmaceuticals in a research note on Wednesday, August 26th. BTIG Research reiterated a “buy” rating and issued a $10.00 price objective on shares of NRx Pharmaceuticals in a report on Monday, September 14th. Wall Street Zen lowered NRx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, Wolfe Research assumed coverage on NRx Pharmaceuticals in a report on Thursday, October 15th. They set an “outperform” rating for the company. Six investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.50.
View Our Latest Analysis on NRx Pharmaceuticals
NRx Pharmaceuticals Stock Performance
NRXP stock opened at $2.49 on Thursday. NRx Pharmaceuticals has a 52 week low of $1.62 and a 52 week high of $5.05. The firm’s fifty day moving average is $2.98 and its 200 day moving average is $2.96. The firm has a market cap of $107.82 million, a P/E ratio of -4.53 and a beta of 2.11.
NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) last released its earnings results on Friday, August 14th. The company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.33). The company had revenue of $1.10 million during the quarter, compared to analyst estimates of $1.33 million.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the business. Commonwealth Equity Services LLC boosted its holdings in NRx Pharmaceuticals by 30.0% in the third quarter. Commonwealth Equity Services LLC now owns 590,768 shares of the company’s stock valued at $1,725,000 after acquiring an additional 136,350 shares in the last quarter. SBI Securities Co. Ltd. grew its holdings in shares of NRx Pharmaceuticals by 292.1% during the 3rd quarter. SBI Securities Co. Ltd. now owns 20,001 shares of the company’s stock worth $58,000 after acquiring an additional 14,900 shares during the period. Prime Capital Investment Advisors LLC purchased a new position in shares of NRx Pharmaceuticals during the 3rd quarter worth approximately $364,000. Squarepoint Ops LLC bought a new position in shares of NRx Pharmaceuticals in the 2nd quarter worth approximately $54,000. Finally, Ethos Financial Group LLC raised its position in shares of NRx Pharmaceuticals by 33.6% in the 1st quarter. Ethos Financial Group LLC now owns 15,900 shares of the company’s stock worth $34,000 after acquiring an additional 4,000 shares in the last quarter. Hedge funds and other institutional investors own 4.27% of the company’s stock.
NRx Pharmaceuticals Company Profile
NRx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, particularly severe depression and suicidal ideation. The company’s research programs are designed to address conditions in which existing therapies may have limited effectiveness or delayed onset.
NRx’s lead investigational product is NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone being developed for bipolar depression with acute suicidal ideation.
Read More
- Five stocks we like better than NRx Pharmaceuticals
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
